Ultrasonic nebulization platforms for pulmonary drug delivery

Expert Opinion on Drug Delivery

Volumn 7, Issue 6, 2010, Pages 663-679

  Yeo, Leslie Y ^a   Friend, James R ^a   McIntosh, Michelle P ^b   Meeusen, Els Nt ^a   Morton, David Av ^b  

^a MONASH UNIVERSITY   (Australia)

^b MONASH UNIVERSITY   (Australia)

Author keywords

Aerosol; Microfluidics; Nebulizer; Pulmonary; Ultrasonic

Indexed keywords

BRONCHODILATING AGENT;

ACOUSTICS; AEROSOL; ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED DRUG RELEASE; ENCAPSULATION; FLOW RATE; HUMAN; METERED DOSE INHALER; NEBULIZATION; PARTICLE SIZE; PIEZOELECTRICITY; POWDER INHALER; REVIEW; SURFACE TENSION; SUSPENSION; ULTRASOUND TRANSDUCER; VIBRATION;

DRUG DELIVERY SYSTEMS; HUMANS; LUNG; NEBULIZERS AND VAPORIZERS;

EID: 77952688985     PISSN: 17425247     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425247.2010.485608     Document Type: Review

References (119)

1. Pharmaceutical inhalation aerosol technology. Hickey AJ, editor, Marcel Dekker, New York; 2004
2. Dessanges J-F. A history of nebulization. J Aerosol Med 2001;14:65-71
3. Newman SP. Therapeutic aerosol deposition in man. In: Moré F, Dolovich MB, Newhouse MT, Newman SP, editors, Aerosols in medicine. Elsevier, Amsterdam; 1993
4. Pharmaceutical inhalation aerosol technology. Hickey A, editor, Marcel Dekker, New York; 1992
5. Newman SP, Clarke SW. Therapeutic aerosols 1--physical and practical considerations. Thorax 1983;38:881-886
6. Thomas SH, O'Doherty M, Graham A, et al. Pulmonary deposition of nebulised amiloride in cystic fibrosis: comparison of two nebulisers. Thorax 1991;46:717-721
7. Usmani O, Biddiscombe M. Effects of bronchodilator particle size in asthmatic patients using monodisperse aerosols. J Appl Physiol 2003;95:2106-2112
8. Ferrari F, Liu Z-H, Lu Q, et al. Comparison of lung tissue concentrations of nebulized ceftazidime in ventilated piglets: ultrasonic versus vibrating plate nebulizers. Intensive Care Med 2008;34:1718-1923
9. Lewis D. Metered-dose inhalers: actuators old and new. Expert Opin Drug Deliv 2007;4:235-245
10. Frijlink HW, De Boer AH. Dry powder inhalers for pulmonary drug delivery. Expert Opin Drug Deliv 2004;1:67-86
11. Freedman T. Medihaler therapy for bronchial asthma; a new type of aerosol therapy. Postgrad Med J 1956;20:667-673
12. Boulet L. The ozone layer and metered dose inhalers. Can Respir J 1998;5:176-179
13. Smyth HDC. The influence of formulation variables on the performance of alternative propellant-driven metered dose inhalers. Adv Drug Del Rev 2003;55:807-828
14. Vervaet C, Byron PR. Drug-surfactant-propellant interactions in HFA-formulations. Int J Pharm 1999;186:13-30
15. Smyth HDC. Propellant-driven metered-dose inhalers for pulmonary drug delivery. Expert Opin Drug Deliv 2005;2:53-74
16. Morton DA, Harmer Q. Optimising device and formulation to regenerate primary particle distributions for systemic delivery. Proceedings of respiratory drug delivery RDD IX. Palm Springs, CA; 2004. p. 849-852
17. De Oliveira MA, Bruno VF, Ballini LS, et al. Evaluation of an educational program for asthma control in adults. J Asthma 1997;34:395-403
18. Plaza V, Sanchis J, Group C. Medical personnel and patient skill in the use of metered dose inhalers: a multicentric study. Respiration 1998;65:195-198
19. McDonald KJ, Martin GP. Transition to CFC-free metered dose inhalers: into the new millennium. Int J Pharm 2000;201:89-107
20. Melani AS, Zanchetta D, Barbato N, et al. Inhalation technique and variables associated with misuse of conventional metered-dose inhalers and newer dry powder inhalers in experienced adults. Ann Allergy Asthma Immunol 2004;93:439-446
21. Kisch GL, Paloucek FP. Metered-dose inhalers and nebulizers in the acute setting. Ann Pharmacother 1992;26:92-95
22. Sestini P, Cappiello V, Aliani M, et al. Prescription bias and factors associated with improper use of inhalers. J Aerosol Med 2006;19:127-136
23. Chapman KR, Voshaar TH, Virchow JC. Inhaler choice in primary practice. Eur Resp Rev 2005;14:117-122
24. Wilkes W, Fink J, Dhand R. Selecting an accessory device with a metered-dose inhaler: variable influence of accessory devices on fine particle dose, throat deposition, and drug delivery with asynchronous actuation from a metered-dose inhaler. J Aerosol Med 2001;14:351-360
25. Berg E, Madsen J, Bisgaard H. In vitro performance of three combinations of spacers and pressurized metered dose inhalers for treatment in children. Eur Resp J 1998;12:472-476
26. Le Brun PPH, De Boer AH, Heijerman HGM, Frijlink HW. A review of the technical aspects of drug nebulization. Pharm World Sci 2000;22:75-81
27. Wieshammer S, Dreyhaupt J. Dry powder inhalers: which factors determine the frequency of handling errors? Respiration 2008;75:18-25
28. Chrystyn H. Effects of device design on patient compliance: comparing the same drug in different devices. Proceedings of respiratory drug delivery RDD. Europe, Lisbon, Portugal; 2009. p. 105-116
29. Crowder TM, Rosati JA, Schroeter JD, et al. Fundamental effects of particle morphology on lung delivery: predictions of stokes' law and the particular relevance to dry powder inhaler formulation and development. Pharm Res 2002;19:239-245
30. Smyth H. Excipients for pulmonary formulations. In: Katdare A, Chaubal MV, editors, Excipient development for pharmaceutical, biotechnology, and drug delivery systems. Informa Healthcare, New York; 2006
31. Van Campen L. Inhalation products for clinical trials. In: Monkhouse DC, Carney CF, Clark JL, editors, Drug products for clinical trials, Taylor & Francis, New York; 2006
32. Gupta R, Hindle M, Byron PR, et al. Investigation of a novel condensation aerosol generator: solute and solvent effects. Aerosol Sci Technol 2003;37:672-681
33. Clay MM, Clarke SW. Wastage of drug from nebulisers: a review. J R Soc Med 1987;80:38-39
34. Finlay WH. The mechanics of inhaled pharmaceutical aerosols. Elsevier, Amsterdam, The Netherlands; 2001
35. Collis GG, Cole CH, Le Souef PN. Dilution of nebulised aerosols by air entrainment in children. Lancet 1990;336:341-343
36. McCallion ONM, Taylor KMG, Bridges PA, et al. Jet nebulisers for pulmonary drug delivery. Int J Pharm 1996;130:1-11
37. O'Callaghan C, Barry PW. The science of nebulised drug delivery. Thorax 1997;52:S31-S44
38. Taylor KMG, Mccallion ONM. Ultrasonic nebulisers for pulmonary drug delivery. Int J Pharm 1997;153:93-104
39. Wood RW, Loomis AL. The physical and biological effects of high frequency sound waves of great intensity. Philos Mag 1927;4:417-436
40. Sollner K. Experiments to demonstrate cavitation caused by ultrasonic waves. Trans Faraday Soc 1936;32:1537-1539
41. Plesset MS, Prosperetti A. Bubble dynamics and cavitation. Annu Rev Fluid Mech 1977;9:145-185
42. Gershenzon EL, Eknadiosyants OK. The nature of liquid atomization in an ultrasonic fountain. Sov Phys Acoust 1964;10:127-132
43. E ́ knadiosyants OK. The kinetics of ultrasonic fog formation. Sov Phys Acoust 1963;9:201-202
44. Boguslavskii YY, E ́ knadiosyants OK. Physical mechanism of the acoustic atomization of a liquid. Sov Phys Acoust 1969;15:14-21
45. Flament MP, Leterme P, Gayot A. Study of the technological parameters of ultrasonic nebulization. Drug Dev Ind Pharm 2001;27:643-649
46. Faraday M. On a peculiar class of acoustical figures and on certain forms assumed by groups of particles upon vibrating elastic surfaces. Philos Trans R Soc London 1831;121:299-340
47. Kelvin WT. Hydrokinetic solutions and observations. Philos Mag 1871;42:362-377
48. Rayleigh B. On the crispations of fluid resting upon a vibrating support. Philos Mag 1883;16:50-58
49. Yule AJ, Al-Suleimani Y. On droplet formation from capillary waves on a vibrating surface. Proc R Soc London Ser A 2000;456:1069-1085
50. James AJ, Vukasinovic B, Smith MK, Glezer A. Vibration-induced drop atomization and bursting. J Fluid Mech 2003;476:1-28
51. Qi A, Yeo LY, Friend JR. Interfacial destabilization and atomization driven by surface acoustic waves. Phys Fluids 2008;20:074103
52. Eisenmenger W. Dynamic properties of the surface tension of water and aqueous solutions of surface active agents with standing capillary waves in the frequency range from 10 Kc/S to 1.5 Mc/S. Acustica 1959;9:327-340
53. Barreras F, Amaveda H, Lozano A. Transient high-frequency ultrasonic water atomization. Exp Fluids 2002;33:405-413
54. Lang RJ. Ultrasonic atomization of liquids. J Acoust Soc Am 1962;34:6-8
55. Fogler HS, Timmerhaus KD. Ultrasonic atomization studies. J Acoust Soc Am 1966;39:515-518
56. Topp MN. Ultrasonic atomization--a photographic study of the mechanism of disintegration. J Aerosol Sci 1973;4:17-25
57. Rajan R, Pandit AB. Correlations to predict droplet size in ultrasonic atomisation. Ultrasonics 2001;39:235-255
58. Kurosawa M, Futami A, Higuchi T. Characteristics of liquids atomization using surface acoustic wave. Proceedings of international conference on solid-state sensors and actuators (Transducers '97). Chicago, USA; 1997. p. 801-804
59. Peskin RL, Raco RJ. Ultrasonic atomization of liquids. J Acoust Soc Am 1963;35:1378-1381
60. Mccallion ONM, Taylor KMG, Thomas M, Taylor AJ. Nebulization of fluids of different physicochemical properties with air-jet and ultrasonic nebulizers. Pharm Res 1995;12:1682-1688
61. Tarr MA, Zhu G, Browner RF. Fundamental aerosol studies with an ultrasonic nebulizer. Appl Spectrosc 1991;45:1424-1432
62. Benjamin TB, Ursell F. The stability of the plane free surface of a liquid in vertical periodic motion. Proc R Soc London Ser A 1954 225:505-515
63. Miles JW. Nonlinear Faraday resonance. J Fluid Mech 1984;146:285-302
64. Miles J, Henderson D. Parametrically forced surface waves. Annu Rev Fluid Mech 1990;2:143-165
65. Forde G, Williamson T, Friend J. Straightforward biodegradable nanoparticle generation through megahertz-order ultrasonic atomization. Appl Phys Lett 2006;89:064105
66. Morton DA, Jeffreys D, Ziegler L, Zanen P. Workshop on devices: regional issues surrounding regulatory requirements for nebulizers. Proceedings of respiratory drug delivery (RDD). Europe, Lisbon, Portugal; 2009. p. 129-148
67. Hardy JG, Newman SP, Knoch M. Lung deposition from four nebulizers. Respir Med 1993;87:461-465
68. Diot P, et al. Aerosols and anti-infectious agents. J Aerosol Med 2001;14:55-64
69. Malone RA, Hollie MC, Glynn-Barnhart A, Nelson HS. Optimal duration of nebulized albuterol therapy. Chest 1993;104:1114-1118
70. Katial RK, Reisner C, Buchmeier A, et al. Comparison of three commercial ultrasonic nebulizers. Ann Allergy Asthma Immunol 2000;84:255-261
71. O'Doherty M, Thomas SHL, Page C, et al. Delivery of a nebulised aerosol to a lung model during mechanical ventilation. Am Rev Respir Dis 1992;146:383-388
72. Pedersen KM, Handlos VN, Heslet L, Kristensen HG. Factors influencing the in vitro deposition of tobramycin aerosol: a comparison of an ultrasonic nebulizer and a high-frequency vibrating mesh nebulizer. J Aerosol Med 2006;19:175-183
73. Mercer TT. Production of therapeutic aerosols. Principles and techniques. Chest 1981;80:813-818
74. Copley M. Nebulizer testing. In: Inhalation. CSC publishing, St Paul, MN; 2008. p. 31-34
75. Thomas S, O'Doherty M, Page C, Nunan T. Variability in the measurement of nebulized aerosol deposition in man. Clin Sci 1991;81:767-775
76. Chinn S, Britton JR, Burney PG, et al. Estimation and repeatability of the response of inhaled histamine in a community survey. Thorax 1987;42:45-52
77. Prokop RM, Finlay WH, Stapleton KW, Zuberbuhler P. The effect of ambient relative humidity on regional dosages delivered by a jet nebulizer. J Aerosol Med 1995;8:363-372
78. Williams L, Fletcher GC, Daniel M, Kinsella J. A simple in vitro method for the evaluation of an ultrasonic nebulizer for drug delivery to intubated, ventilated patients and the effect of nebulizer and ventilator settings on the uptake of fluid from the nebulizer chamber. Eur J Anaesthesiol 1999;16:479-484
79. Everard ML, Hardy JG, Milner AD. Comparison of nebulised aerosol deposition in the lungs of healthy adults following oral and nasal inhalation. Thorax 1993;48:1045-1046
80. Bennett WD. Human variation in spontaneous breathing deposition fraction: a review. J Aerosol Med 1988;1:67-80
81. Anderson SD. Bronchial challenge by ultrasonically nebulized aerosols. Clin Rev Allergy 1985;3:427-439
82. Berger WE. Paediatric pulmonary drug delivery: considerations in asthma treatment. Expert Opin Drug Deliv 2005;2:965-980
83. Fok TF, Lam K, Ng PC, et al. Delivery of salbutamol to nonventilated preterm infants by metered-dose inhaler, jet nebulizer, and ultrasonic nebulizer. Eur Resp J 1998;12:159-164
84. Nakanishi AK, Lamb BM, Foster C, Rubin BK. Ultrasonic nebulization of albuterol is no more effective than jet nebulization for the treatment of acute asthma in children. Chest 1997;111:1505-1508
85. Heyder J, Gebhart J, Scheuch G. Influence of human lung morphology on particle deposition. J Aerosol Med 1988;1:81-88
86. Smith AL, Ramsey B. Aerosol administration of antibiotics. Respiration 1995;62:19-24
87. Dalby R, Suman J. Inhalation therapy: technological milestones in asthma treatment. Adv Drug Del Rev 2003;55:779-791
88. Dennis JH, Hendrick DJ. Design characteristics for drug nebulizers. J Med Eng Technol 1992;16:63-68
89. Fok TF, Al-Essa M, Monkman S, et al. Pulmonary deposition of salbutamol aerosol delivered by metered dose inhaler, jet nebulizer, and ultrasonic nebulizer in mechanically ventilated rabbits. Pediatr Res 1997;42:721-727
90. Finlay WH, Stapleton KW, Zuberbuhler P. Variations in predicted regional lung deposition of salbutamol sulphate between 19 nebulizer types. J Aerosol Med 1998;11:65-80
91. Cryana S-A, Sivadas N, Garcia-Conteras L. In vivo animal models for drug delivery across the lung mucosal barrier. Adv Drug Del Rev 2007;59:1133-1151
92. Meeusen EN, Snibson KJ, Hirst SJ, Bischof RJ. Sheep as a model species for the study and treatment of human asthma and other respiratory diseases. Drug Discov Today Dis Models 2010 DOI:10.1016/ j.ddmod.2009.1012.1002
93. Steckel H, Eskandar F. Factors affecting aerosol performance during nebulization with jet and ultrasonic nebulizers. Eur J Pharm Sci 2003;19:443-455
94. Weber A, Morlin G, Cohen M, et al. Effect of nebulizer type and antibiotic concentration on device performance. Pediatr Pulmonol 1997;23:249-260
95. Shen S-C, Wang Y-J, Chen Y-Y. Design and fabrication of medical micro-nebulizer. Sens Actuators A 2008;144:135-143
96. Nikander K, Turpeinen M, Wollmer P. The conventional ultrasonic nebulizer proved inefficient in nebulizing a suspension. J Aerosol Med 1999;12:47-53
97. Le Brun PPH, De Boer AH, Gjaltema D, et al. Inhalation of tobramycin in cystic fibrosis: part 1: the choice of a nebulizer. Int J Pharm 1999 189:205-214
98. Le Brun PPH, De Boer AH, Gjaltema D, et al. Inhalation of tobramycin in cystic fibrosis: part 2: optimization of the tobramycin solution for a jet and an ultrasonic nebulizer. Int J Pharm 1999;189:215-225
99. Touw DJ, Jacobs FA, Brimicombe RW, et al. Pharmacokinetics of aerosolized tobramycin in adult patients with cystic fibrosis. Antimicrob Agents Chemother 1997;41:184-187
100. Fernandes CA, Vanbever R. Preclinical models for pulmonary drug delivery. Expert Opin Drug Deliv 2009;6:1231-1245
101. Terzano C, Allegra L. Importance of drug delivery system in steroid aerosol therapy via nebulizer. Pulm Pharmacol Ther 2002;15:449-454
102. Maehara N, Ueha S, Mori E. Influence of the vibrating system of a multipinhole-plate ultrasonic nebulizer on its performance. Rev Sci Instrum 1986;57:2870-2876
103. Biskos G, Vons V, Yurteri CU, Schmidt-Ott A. Generation and sizing of particles for aerosol-based nanotechnology. KONA Powder Particle J 2008;26:13-35
104. Newman SP. Aerosols. In: Laurent GJ, Shapiro SD, editors, Encyclopedia of respiratory medicine. Elsevier, Amsterdam; 2006
105. Knoch M, Keller M. The customised electronic nebuliser: a new category of liquid aerosol drug delivery systems. Expert Opin Drug Deliv 2005;2:377-390
106. Lass JS, Sant A, Knoch M. New advances in aerosolised drug delivery: vibrating membrane nebuliser technology. Expert Opin Drug Deliv 2006;3:693-702
107. Berglund RN, Liu BYH. Generation of monodisperse aerosol standards. Environ Sci Technol 1973;7:147-153
108. Denyer J, Nikander K, Smith NJ. Adaptive aerosol delivery (AAD) technology. Expert Opin Drug Deliv 2004;1:165-176
109. Qi A, Friend JR, Yeo LY, et al. Miniature inhalation therapy platform using surface acoustic wave microfluidic atomization. Lab Chip 2009;9:2184-2193
110. Yeo LY, Friend JR. Ultrafast microfluidics using surface acoustic waves. Biomicrofluidics 2009;3:012002
111. Alvarez M, Friend JR, Yeo LY. Surface vibration induced spatial ordering of periodic polymer patterns on a substrate. Langmuir 2008;24:10629-10632
112. Qi A, Yeo L, Friend J, Ho J. The extraction of liquid, protein molecules and yeast cells from paper through surface acoustic wave atomization. Lab Chip 2010;10:470-476
113. Li H, Friend J, Yeo L, et al. Effect of surface acoustic waves on the viability, proliferation and differentiation of primary osteoblast-like cells. Biomicrofluidics 2009;3:034102
114. Fink JB. Aerosol device selection: evidence to practice. Respir Care 2000;45:874-885
115. Alvarez M, Friend J, Yeo LY. Rapid generation of protein aerosols and nanoparticles via surface acoustic wave atomization. Nanotechnology 2008;19:455103
116. Alvarez M, Yeo LY, Friend JR, Jamriska M. Rapid production of protein-loaded biodegradable microparticles using surface acoustic waves. Biomicrofluidics 2009;3:014102
117. Friend JR, Yeo LY, Arifin DR, Mechler A. Evaporative self-assembly assisted synthesis of polymeric nanoparticles by surface acoustic wave atomization. Nanotechnology 2008;19:145301
118. Pedersen S. Inhalers and nebulizers: which to choose and why. Respir Med 1996;90:69-77
119. Boulton-Stone JM, Blake JR. Gas bubbles bursting at a free surface. J Fluid Mech 1993;254:437-466